Christopher M Gamboa1, Monika M Safford, Emily B Levitan, Devin M Mann, Huifeng Yun, Stephen P Glasser, J Michael Woolley, Robert Rosenson, Michael Farkouh, Paul Muntner. 1. Department of Epidemiology (CMG, EBL, HY, PM), University of Alabama at Birmingham, Birmingham, Alabama; Division of Preventive Medicine (CMG, MMS, SG), University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine - Section of Preventive Medicine and Epidemiology (DMM), Boston University, Boston, Massachusetts; Center for Observational Research (JMW), Amgen, Inc., Thousand Oaks, California; Mount Sinai Heart (RR, MK), Icahn School of Medicine at Mount Sinai, New York City, New York.
Abstract
BACKGROUND: Statins reduce the risk of coronary heart disease (CHD) in individuals with a history of CHD or risk equivalents. A 10-year CHD risk >20% is considered a risk equivalent but is frequently not detected. Statin use and low-density lipoprotein cholesterol (LDL-C) control were examined among participants with CHD or risk equivalents in the nationwide Reasons for Geographic and Racial Differences in Stroke study (n = 8812). METHODS: Participants were categorized into 4 mutually exclusive groups: (1) history of CHD (n = 4025); (2) no history of CHD but with a history of stroke and/or abdominal aortic aneurysm (AAA) (n = 946); (3) no history of CHD or stroke/AAA but with diabetes mellitus (n = 3134); or (4) no history of the conditions in (1) through (3) but with 10-year Framingham CHD risk score (FRS) >20% calculated using the third Adult Treatment Panel point scoring system (n = 707). RESULTS: Statins were used by 58.4% of those in the CHD group and 41.7%, 40.4% and 20.1% of those in the stroke/AAA, diabetes mellitus and FRS >20% groups, respectively. Among those taking statins, 65.1% had LDL-C <100 mg/dL, with no difference between the CHD, stroke/AAA, or diabetes mellitus groups. However, compared with those in the CHD group, LDL-C <100 mg/dL was less common among participants in the FRS >20% group (multivariable adjusted prevalence ratio: 0.72; 95% confidence interval: 0.62-0.85). Results were similar using the 2013 American College of Cardiology/American Heart Association cholesterol treatment guideline. CONCLUSIONS: These data suggest that many people with high CHD risk, especially those with an FRS >20%, do not receive guideline-concordant lipid-lowering therapy and do not achieve an LDL-C <100 mg/dL.
BACKGROUND: Statins reduce the risk of coronary heart disease (CHD) in individuals with a history of CHD or risk equivalents. A 10-year CHD risk >20% is considered a risk equivalent but is frequently not detected. Statin use and low-density lipoprotein cholesterol (LDL-C) control were examined among participants with CHD or risk equivalents in the nationwide Reasons for Geographic and Racial Differences in Stroke study (n = 8812). METHODS:Participants were categorized into 4 mutually exclusive groups: (1) history of CHD (n = 4025); (2) no history of CHD but with a history of stroke and/or abdominal aortic aneurysm (AAA) (n = 946); (3) no history of CHD or stroke/AAA but with diabetes mellitus (n = 3134); or (4) no history of the conditions in (1) through (3) but with 10-year Framingham CHD risk score (FRS) >20% calculated using the third Adult Treatment Panel point scoring system (n = 707). RESULTS: Statins were used by 58.4% of those in the CHD group and 41.7%, 40.4% and 20.1% of those in the stroke/AAA, diabetes mellitus and FRS >20% groups, respectively. Among those taking statins, 65.1% had LDL-C <100 mg/dL, with no difference between the CHD, stroke/AAA, or diabetes mellitus groups. However, compared with those in the CHD group, LDL-C <100 mg/dL was less common among participants in the FRS >20% group (multivariable adjusted prevalence ratio: 0.72; 95% confidence interval: 0.62-0.85). Results were similar using the 2013 American College of Cardiology/American Heart Association cholesterol treatment guideline. CONCLUSIONS: These data suggest that many people with high CHD risk, especially those with an FRS >20%, do not receive guideline-concordant lipid-lowering therapy and do not achieve an LDL-C <100 mg/dL.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard Journal: Neuroepidemiology Date: 2005-06-29 Impact factor: 3.282
Authors: Lori Mosca; Allison H Linfante; Emelia J Benjamin; Kathy Berra; Sharonne N Hayes; Brian W Walsh; Rosalind P Fabunmi; Johnny Kwan; Thomas Mills; Susan Lee Simpson Journal: Circulation Date: 2005-02-01 Impact factor: 29.690
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Circulation Date: 2004-07-13 Impact factor: 29.690
Authors: Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan Journal: Ann Intern Med Date: 2003-07-15 Impact factor: 25.391
Authors: Khoa A Nguyen; Lang Li; Deshun Lu; Aida Yazdanparast; Lei Wang; Rolf P Kreutz; Elizabeth C Whipple; Titus K Schleyer Journal: Eur J Clin Pharmacol Date: 2018-05-22 Impact factor: 2.953
Authors: Seamus C Harrison; Michael V Holmes; Stephen Burgess; Folkert W Asselbergs; Gregory T Jones; Annette F Baas; F N van 't Hof; Paul I W de Bakker; Jan D Blankensteijn; Janet T Powell; Athanasios Saratzis; Gert J de Borst; Daniel I Swerdlow; Yolanda van der Graaf; Andre M van Rij; David J Carey; James R Elmore; Gerard Tromp; Helena Kuivaniemi; Robert D Sayers; Nilesh J Samani; Matthew J Bown; Steve E Humphries Journal: JAMA Cardiol Date: 2018-01-01 Impact factor: 14.676
Authors: Kaylee B Crockett; Ying Wen; Edgar T Overton; Elizabeth A Jackson; Robert S Rosenson; Paul Muntner; Lisandro D Colantonio Journal: J Clin Lipidol Date: 2020-11-11 Impact factor: 4.766
Authors: Giuseppe Penno; Anna Solini; Giacomo Zoppini; Cecilia Fondelli; Roberto Trevisan; Monica Vedovato; Gabriella Gruden; Olga Lamacchia; Antonio E Pontiroli; Maura Arosio; Emanuela Orsi; Giuseppe Pugliese Journal: PLoS One Date: 2015-05-05 Impact factor: 3.240
Authors: F D Richard Hobbs; Maciej Banach; Dimitri P Mikhailidis; Aseem Malhotra; Simon Capewell Journal: BMC Med Date: 2016-01-14 Impact factor: 8.775